Literature DB >> 19745065

The effect of plasma from muscle-specific tyrosine kinase myasthenia patients on regenerating endplates.

W Pascale ter Beek1, Pilar Martínez-Martínez, Mario Losen, Marc H de Baets, Axel R Wintzen, Jan J G M Verschuuren, Erik H Niks, Sjoerd G van Duinen, Angela Vincent, Peter C Molenaar.   

Abstract

Muscle-specific tyrosine kinase (MuSK) is essential for clustering of acetylcholine receptors (AChRs) at embryogenesis and likely also important for maintaining synaptic structure in adult muscle. In 5 to 7% of myasthenia gravis (MG) cases, the patients' blood contains antibodies to MuSK. To investigate the effect of MuSK-MG antibody on synapse regeneration, notexin was used to induce damage to the flexor digitorum brevis muscle. We administered aliquots of MuSK-MG patients' plasma to the flexor digitorum brevis twice daily for a period up to 21 days, and muscles were investigated ex vivo in contraction experiments. AChR levels were measured with (125)I-alpha-bungarotoxin, and endplates were studied with quantitative immunohistochemistry. In normal muscles and in 14-day regenerated muscles, MuSK plasma caused impairment of nerve stimulus-induced contraction in the presence of 0.35 and 0.5 mmol/L Ca(2+) with or without 100 to 400 nmol/L tubocurarine. Endplate size was decreased in regenerated muscles relative to controls; however, we did not observe such differences in muscle not treated with notexin. MuSK plasma had no effect on the amount and turnover rate of AChRs. Our results suggest that anti-MuSK antibodies influence the activity of MuSK molecules without reducing their number, thereby diminishing the size of the endplate and affecting the functioning of AChRs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19745065      PMCID: PMC2751550          DOI: 10.2353/ajpath.2009.090040

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  48 in total

1.  Effect of reinnervation on the degradation rate of junctional acetylcholine receptors synthesized in denervated skeletal muscles.

Authors:  S L Shyng; M M Salpeter
Journal:  J Neurosci       Date:  1990-12       Impact factor: 6.167

2.  Neuromuscular transmission at newly formed neuromuscular junctions in the regenerating soleus muscle of the rat.

Authors:  B D Grubb; J B Harris; I S Schofield
Journal:  J Physiol       Date:  1991-09       Impact factor: 5.182

Review 3.  The agrin hypothesis.

Authors:  U J McMahan
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1990

4.  The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo.

Authors:  T M DeChiara; D C Bowen; D M Valenzuela; M V Simmons; W T Poueymirou; S Thomas; E Kinetz; D L Compton; E Rojas; J S Park; C Smith; P S DiStefano; D J Glass; S J Burden; G D Yancopoulos
Journal:  Cell       Date:  1996-05-17       Impact factor: 41.582

5.  MUSK, a new target for mutations causing congenital myasthenic syndrome.

Authors:  Frédéric Chevessier; Brice Faraut; Aymeric Ravel-Chapuis; Pascale Richard; Karen Gaudon; Stéphanie Bauché; Cassandra Prioleau; Ruth Herbst; Evelyne Goillot; Christine Ioos; Jean-Philippe Azulay; Shahram Attarian; Jean-Paul Leroy; Emmanuel Fournier; Claire Legay; Laurent Schaeffer; Jeanine Koenig; Michel Fardeau; Bruno Eymard; Jean Pouget; Daniel Hantaï
Journal:  Hum Mol Genet       Date:  2004-10-20       Impact factor: 6.150

6.  Passive transfer of seronegative myasthenia gravis to mice.

Authors:  J Burges; A Vincent; P C Molenaar; J Newsom-Davis; C Peers; D Wray
Journal:  Muscle Nerve       Date:  1994-12       Impact factor: 3.217

7.  Lrp4 is a receptor for Agrin and forms a complex with MuSK.

Authors:  Natalie Kim; Amy L Stiegler; Thomas O Cameron; Peter T Hallock; Andrea M Gomez; Julie H Huang; Stevan R Hubbard; Michael L Dustin; Steven J Burden
Journal:  Cell       Date:  2008-10-09       Impact factor: 41.582

8.  Molecular cloning and functional analysis of the promoter of rat skeletal muscle voltage-sensitive sodium channel subtype 2 (rSkM2): evidence for muscle-specific nuclear protein binding to the core promoter.

Authors:  Z H Sheng; H Zhang; R L Barchi; R G Kallen
Journal:  DNA Cell Biol       Date:  1994-01       Impact factor: 3.311

9.  Plasma from patients with seronegative myasthenia gravis inhibit nAChR responses in the TE671/RD cell line.

Authors:  R Barrett-Jolley; N Byrne; A Vincent; J Newsom-Davis
Journal:  Pflugers Arch       Date:  1994-10       Impact factor: 3.657

10.  Failure of postsynaptic specialization to develop at neuromuscular junctions of rapsyn-deficient mice.

Authors:  M Gautam; P G Noakes; J Mudd; M Nichol; G C Chu; J R Sanes; J P Merlie
Journal:  Nature       Date:  1995-09-21       Impact factor: 49.962

View more
  14 in total

1.  In response to "current approach to seronegative myasthenia" by Z. Argov.

Authors:  Michal Haran
Journal:  J Neurol       Date:  2010-11-18       Impact factor: 4.849

2.  Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis.

Authors:  Chengyong Shen; Yisheng Lu; Bin Zhang; Dwight Figueiredo; Jonathan Bean; Jiung Jung; Haitao Wu; Arnab Barik; Dong-Min Yin; Wen-Cheng Xiong; Lin Mei
Journal:  J Clin Invest       Date:  2013-11-08       Impact factor: 14.808

3.  Anti-MuSK autoantibodies block binding of collagen Q to MuSK.

Authors:  Y Kawakami; M Ito; M Hirayama; K Sahashi; B Ohkawara; A Masuda; H Nishida; N Mabuchi; A G Engel; K Ohno
Journal:  Neurology       Date:  2011-10-19       Impact factor: 9.910

4.  Acute severe animal model of anti-muscle-specific kinase myasthenia: combined postsynaptic and presynaptic changes.

Authors:  David P Richman; Kayoko Nishi; Stuart W Morell; Jolene Mi Chang; Michael J Ferns; Robert L Wollmann; Ricardo A Maselli; Joachim Schnier; Mark A Agius
Journal:  Arch Neurol       Date:  2011-12-12

5.  Patient autoantibodies deplete postsynaptic muscle-specific kinase leading to disassembly of the ACh receptor scaffold and myasthenia gravis in mice.

Authors:  R N Cole; N Ghazanfari; S T Ngo; O L Gervásio; S W Reddel; W D Phillips
Journal:  J Physiol       Date:  2010-07-05       Impact factor: 5.182

6.  Animal models of antimuscle-specific kinase myasthenia.

Authors:  David P Richman; Kayoko Nishi; Michael J Ferns; Joachim Schnier; Peter Pytel; Ricardo A Maselli; Mark A Agius
Journal:  Ann N Y Acad Sci       Date:  2012-12       Impact factor: 5.691

Review 7.  The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis.

Authors:  Inga Koneczny; Judith Cossins; Angela Vincent
Journal:  J Anat       Date:  2013-03-04       Impact factor: 2.610

Review 8.  Muscle autoantibodies in myasthenia gravis: beyond diagnosis?

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Expert Rev Clin Immunol       Date:  2012-07       Impact factor: 4.473

9.  Autoantibodies to agrin in myasthenia gravis patients.

Authors:  Bin Zhang; Chengyong Shen; Beverly Bealmear; Samia Ragheb; Wen-Cheng Xiong; Richard A Lewis; Robert P Lisak; Lin Mei
Journal:  PLoS One       Date:  2014-03-14       Impact factor: 3.240

Review 10.  Autoantibodies to neurotransmitter receptors and ion channels: from neuromuscular to neuropsychiatric disorders.

Authors:  Pilar Martinez-Martinez; Peter C Molenaar; Mario Losen; Jo Stevens; Marc H De Baets; Andrei Szoke; Jerome Honnorat; Ryad Tamouza; Marion Leboyer; Jim Van Os; Bart P F Rutten
Journal:  Front Genet       Date:  2013-09-20       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.